CABA - Cabaletta Bio gains on FDA fast-track tags for lead asset
2024-01-08 15:05:33 ET
More on Cabaletta Bio
- Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology
- Buy Cabaletta Bio's Promising SLE Treatment
- Cabaletta Bio GAAP EPS of -$0.37 beats by $0.04
- Cantor starts Cabaletta at overweight, cites "strong" position in CART-T drugs
- Seeking Alpha’s Quant Rating on Cabaletta Bio
For further details see:
Cabaletta Bio gains on FDA fast-track tags for lead asset